Can This Blockbuster Drug Continue to Grow?

Eli Lilly is one of today's biggest players in the erectile dysfunction space. Its drug Cialis garnered more than $1.9 billion in 2012, but how important is this single therapeutic to Lilly's total business? What are the competitive dynamics of the erectile dysfunction market, and how do Pfizer's Viagra and VIVUS' drug Stendra compare to Cialis? In this video, health care analyst Max Macaluso examines these issues for investors.

Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

The article Can This Blockbuster Drug Continue to Grow? originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.